Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Synthesis
Novartis To Speed Vaccine Creation
by Ann M. Thayer
October 18, 2010
| A version of this story appeared in
Volume 88, Issue 42
Novartis hopes to accelerate the production of influenza vaccines by working with Synthetic Genomics Vaccines, a new company created by Synthetic Genomics and the not-for-profit J. Craig Venter Institute. Instead of relying on viruses identified and supplied by health organizations for making vaccines, the partners will computationally design and synthetically construct a bank of seed viruses. These seed strains can be put into production up to two months faster in the event of a flu outbreak, the partners say.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter